Black Diamond Therapeutics (NASDAQ:BDTX) & Vericel (NASDAQ:VCEL) Financial Comparison

Vericel (NASDAQ:VCEL) and Black Diamond Therapeutics (NASDAQ:BDTX) are both healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their risk, institutional ownership, profitability, earnings, valuation, analyst recommendations and dividends.

Institutional and Insider Ownership

95.5% of Black Diamond Therapeutics shares are owned by institutional investors. 7.6% of Vericel shares are owned by company insiders. Comparatively, 9.3% of Black Diamond Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Volatility & Risk

Vericel has a beta of 1.08, suggesting that its share price is 8% more volatile than the S&P 500. Comparatively, Black Diamond Therapeutics has a beta of 3.48, suggesting that its share price is 248% more volatile than the S&P 500.

Profitability

This table compares Vericel and Black Diamond Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Vericel	10.27%	9.09%	6.68%
Black Diamond Therapeutics	N/A	-36.66%	-28.44%

Analyst Recommendations

This is a breakdown of recent ratings and recommmendations for Vericel and Black Diamond Therapeutics, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Vericel	0	1	5	1	3.00
Black Diamond Therapeutics	1	2	7	0	2.60

Vericel presently has a consensus target price of $62.00, indicating a potential upside of 8.85%. Black Diamond Therapeutics has a consensus target price of $11.00, indicating a potential upside of 648.30%. Given Black Diamond Therapeutics’ higher probable upside, analysts plainly believe Black Diamond Therapeutics is more favorable than Vericel.

Valuation and Earnings

This table compares Vericel and Black Diamond Therapeutics”s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Vericel	$276.26 million	10.52	$16.52 million	$0.64	89.00
Black Diamond Therapeutics	$70.00 million	1.21	$22.37 million	($0.77)	-1.91

Black Diamond Therapeutics has lower revenue, but higher earnings than Vericel. Black Diamond Therapeutics is trading at a lower price-to-earnings ratio than Vericel, indicating that it is currently the more affordable of the two stocks.

Summary

Vericel beats Black Diamond Therapeutics on 9 of the 15 factors compared between the two stocks.

About Vericel

Vericel Corporation is a biopharmaceutical company focused on developing and commercializing cell therapies and other treatments for serious conditions. Based in Cambridge, Massachusetts, the company markets its products primarily in the United States. Its products include MACI, an implant made from a patient’s own cultured cartilage cells used to repair certain cartilage defects in the knee, and Epicel, a cultured skin graft used to treat patients with deep burns. Vericel also commercializes NexoBrid in the United States, an enzyme-based treatment for removing dead tissue from severe thermal burns.

About Black Diamond Therapeutics

Black Diamond Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing precision medicines for people with genetically defined cancers. The company uses its discovery platform to identify cancer-causing mutations and develop small-molecule therapies designed to target them. Its pipeline has included BDTX-1535, an investigational inhibitor designed to target certain EGFR alterations in cancers such as non-small cell lung cancer. The company’s candidates are in clinical development; it does not have an approved commercial product.